[1]莫淼,王靖雯,张剑.激素受体阳性､ 人表皮生长因子受体阴性､ 腋窝淋巴结阴性､ OncotypeDX21 基因评分中等风险的早期乳腺癌患者单纯内分泌治疗与化疗联合内分泌治疗的比较—TAI-LORx 研究解读[J].中国癌症杂志,2018,28(8):634-640.DOI:10.19401/j.cnki.1007-3639.2018.08.012.[2]汪林军,王腾,吴小红,等.血浆微泡乳腺癌耐药蛋白mRNA 水平对乳腺癌化疗疗效的预测价值 [J]. 中华实验外科杂志, 2015,32(5):976-978.[3]Kaufmann M,von Minckwitz G,Smith R,et al.Interna-tional Expert Panel on the Use of Primary (Preoperative)Systemic Treatment of Operable Breast Cancer:Review and Recommendations[J].Journal of Clinical Oncology,2003,21(13):2600-2608.[4]Colleoni M,Viale G,Zahrieh D,et al.Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors:A Study of Preoperative Treatmen-t [J]. Clinical Cancer Research,2004,10(19):6622-6628.[5]Cortazar P,Zhang L,Untch M,et al.Pathologicalcomplete response and longterm clinical benefifit in breast cancer:the CT NeoBC pooled analysis[J].Lancet,2014,384(9938):164-172.[6]Chollet P,Amat S,Cure H,et al.Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer [J].British Journal of Cancer,2002,86(7): 1041-1046.[7] 李天翔. 内分泌联合辅助化疗治疗对乳腺癌患者临床疗效和生活质量的影响观察[J].现代诊断与治疗 ,2017,28(18):3348-3349.DOI:10.3969/j.issn.1001-8174.2017.18.009.[8]Fontein DB,Charehbili A,Nortier JW,et al.Efficacy of six month neoadjuvant endocrine therapy in postmenopausal,hormone receptor-positive breast cancer patients-A phaseⅡtrial.[9]钟海鸣,莫淑芬,吴昱冶新辅助化疗联合内分泌治疗乳腺癌疗效观察临床合理用药[J]2020 , 3(13) 10. 15887 /j. cnki. 13-1389 /r. 2020. 07. 035[10]郭德阳,陈雷,王劲松,等.芳香化酶抑制剂用于绝经后激素依赖性乳腺癌患者新辅助内分泌治疗效果的Meta 分析[J].第三军医大学学报,2016,38(7):781-786.DOI:10. 16016 /j. 1000-5404.201511196.[11]王雪宁,朱明慧,纪增辉,等.乳腺癌术后新辅助化疗 联 合 内 分 泌 治 疗 的 临 床 疗 效 分 析 [J]. 医 疗 装备,2016,29(2):142-143.DOI:10.3969/j.issn.1002-2376.2016.02.098.[12]单孝军,刘鹏宇.新辅助化疗联合保乳手术治疗乳腺癌的临床研究[J].中国医药导报,2011,8(7):32-34.DOI:10.3969 /j.issn. 1673-7210. 2011. 07. 013.
